Alchemia Limited (ASX:ACL) has been granted an ASX trading halt in relation to its profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015.
The halt will last until the earlier of the announcement being made or the commencement of trade on Tuesday, 26th May 2015.
Fondaparinux, a generic version of GlaxoSmithKline’s Arixtra, is FDA approved and targets the multi-billion dollar heparin-drug market.
The company received its first profits from its sales in August 2011.
News: Alchemia Limited in halt relating to profit share for anti-coagulant drug
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable